Search results for "Intestin"

showing 10 items of 2215 documents

Use of BICAP in a case of colon angiodysplasia

1991

This paper reports on a case of colonic bleeding from an angiodysplastic lesion of the ascending colon in a 71-year-old diabetic woman, resulting in severe anemia in the patient, who was treated using the BICAP electrocoagulation system. The present report includes a description of this technique, which involves the use of a 7-F hemostatic probe connected to a 25-W BICAP source.

medicine.medical_specialtymedicine.medical_treatmentColonoscopyElectrocoagulationAngiodysplasiaLesionColonic DiseasesInternal medicineElectrocoagulationmedicineHumansAscending colonAgedmedicine.diagnostic_testbusiness.industryColon angiodysplasiaHepatologymedicine.diseaseSurgeryDysplasiaFemaleSurgerymedicine.symptomGastrointestinal HemorrhagebusinessAbdominal surgerySurgical Endoscopy
researchProduct

An unusual association of left‐sided gastroschisis and persistent right umbilical vein

2018

Key Clinical Message Gastroschisis is a full‐thickness congenital abdominal wall defect usually occurring to the right of the umbilicus. About twenty cases of left‐sided gastroschisis have been reported, without reference to the laterality of the umbilical vein. This first case highlights the importance of considering and reporting this association by the perinatal team.

medicine.medical_specialtyprenatal diagnosisGastroschisisbusiness.industryUmbilicus (mollusc)Abdominal wall defectPrenatal diagnosisGeneral Medicinegastrointestinal malformation030204 cardiovascular system & hematologymedicine.diseaseLeft sidedUmbilical veinRight umbilical veinSurgery03 medical and health sciencesabdominal wall defect0302 clinical medicineClinical Images030220 oncology & carcinogenesisClinical ImageLateralitymedicinebusinessClinical Case Reports
researchProduct

Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells

2013

Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced HCC. However, although sorafenib is well tolerated, concern for its safety has been expressed. Celecoxib (Celebrex®) is a selective cyclooxygenase-2 (COX-2) inhibitor which exhibits antitumor effects in human HCC cells. The present study examined the interaction between celecoxib and sorafenib in two human liver tumor cell lines HepG2 and Huh7. Our data showed that each inhibitor alone reduced cell growth and the combination of celecoxib with sorafenib synergistically inhibited cell growth an…

medicine.medical_treatmentCancer TreatmentGene ExpressionApoptosisPharmacologyBiochemistryTargeted therapy0302 clinical medicineMolecular Cell Biology0303 health sciencesSulfonamidesMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionQLiver NeoplasmsRDrug SynergismGenomicsSorafenib3. Good healthGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesisMedicineLiver cancermedicine.drugResearch ArticleBiotechnologySignal TransductionSorafenibNiacinamideProgrammed cell deathCarcinoma HepatocellularScienceBlotting WesternBiologyMolecular Genetics03 medical and health sciencesCell Line TumorGastrointestinal TumorsmedicineIn Situ Nick-End LabelingHumansneoplasmsBiology030304 developmental biologyCell ProliferationDNA PrimersHuman liver cancer Apoptosis Sorafenib Celecoxib anti-proliferative effectsCell growthGene Expression ProfilingPhenylurea CompoundsComputational BiologyCancers and NeoplasmsHepatocellular CarcinomaChemotherapy and Drug Treatmentmedicine.diseaseMicroarray Analysisdigestive system diseasesGene expression profilingApoptosisCell cultureCelecoxibPyrazolesGenome Expression AnalysisPLoS ONE
researchProduct

Transcription factors controlling development and function of innate lymphoid cells.

2014

Abstract Innate lymphoid cells (ILCs) are a heterogeneous group of lymphocytes, which play an important role in tissue homeostasis at epithelial surfaces. They are scarce in spleen and lymph nodes, but substantial numbers can be found in the intestinal mucosa even at steady state. There, they represent the first line of defence against invading pathogens and contribute to lymphorganogenesis, tissue repair and, when inappropriately activated, immune pathology. Lineage-specific development, function and maintenance of these cells depend on a restricted set of transcription factors that partially emerged as a result of diversification and selection during vertebrate evolution. The differential…

medicine.medical_treatmentImmunologyBiologyLymphocyte ActivationIntestinal mucosaRAR-related orphan receptor gammamedicineTranscriptional regulationImmunology and AllergyAnimalsHomeostasisHumansCell LineageLymphopoiesisLymphocytesIntestinal MucosaTranscription factorTissue homeostasisInnate lymphoid cellGene Expression Regulation DevelopmentalCell DifferentiationGeneral MedicineBiological EvolutionImmunity InnateCytokineImmunologyHost-Pathogen InteractionsCytokinesInterleukin Receptor Common gamma SubunitTranscription FactorsInternational immunology
researchProduct

Novel cytokine-targeted therapies and intestinal inflammation

2009

Several cytokines have been identified as critical mediators of chronic inflammation in inflammatory bowel disease (IBD) and biological therapies that target these molecules have been developed during recent years. Thereby, anti-TNF agents have noticeably improved the treatment of patients with IBD in comparison to conventional therapy. Furthermore, initial clinical trials showed promising results with anti-IL-6 and anti-IL-12/IL-23 agents. In addition to these well-known mediators of IBD, various novel cytokines have been described as critical during the pathogenesis of IBD in recent experimental studies and therapeutic targeting of these cytokines could provide new strategies for human di…

medicine.medical_treatmentInflammationTherapeutic targetingInflammatory bowel diseaseAntibodiesPathogenesisDrug Delivery SystemsIntestinal inflammationDrug DiscoverymedicineAnimalsHumansIntestinal MucosaPharmacologyBiological therapiesbusiness.industryModels ImmunologicalColitisInflammatory Bowel Diseasesmedicine.diseasedigestive system diseasesIntestinesClinical trialDisease Models AnimalCytokineImmunologyCytokinesmedicine.symptombusinessCurrent Opinion in Pharmacology
researchProduct

Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and prot…

2006

ABSTRACTRotavirus (RV) is the main etiological agent of severe gastroenteritis in infants, and vaccination seems the most effective way to control the disease. Recombinant rotavirus-like particles composed of the viral protein 6 (VP6) and VP2 (2/6-VLPs) have been reported to induce protective immunity in mice when administered by the intranasal (i.n.) route. In this study, we show that administration of 2/6-VLPs by the intrarectal (i.r.) route together with either cholera toxin (CT) or a CpG-containing oligodeoxynucleotide as the adjuvant protects adult mice against RV infection. Moreover, when CT is used, RV shedding in animals immunized by the i.r. route is even reduced in comparison with…

medicine.medical_treatmentMESH : Cytokinesanimal diseasesMESH : Oligodeoxyribonucleotidesmedicine.disease_causeAntibodies ViralImmunoglobulin GMiceIntestinal mucosaMESH: RectumRotavirusMESH : FemaleMESH: AnimalsViralIntestinal MucosaInbred BALB C0303 health sciencesMice Inbred BALB CMESH: CytokinesMESH : Cholera ToxinMESH : Immunoglobulin A SecretoryMESH: Rotavirus Infections3. Good healthMESH : Rotavirus VaccinesVaccinationmedicine.anatomical_structureOligodeoxyribonucleotides[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyMESH : RectumMESH: Intestinal MucosaCytokinesMESH: VirionMESH: ImmunizationFemaleAdjuvantMESH : Antibodies ViralCholera ToxinImmunologyMESH: Mice Inbred BALB CSpleenchemical and pharmacologic phenomenaBiologyMicrobiologyMESH : Intestinal Mucosa[ SDV.MP.VIR ] Life Sciences [q-bio]/Microbiology and Parasitology/VirologyMESH: Rotavirus VaccinesRotavirus InfectionsAntibodies03 medical and health sciencesImmune systemVirologyVaccines and Antiviral AgentsMESH : MicemedicineMESH : Rotavirus InfectionsMESH : VirionAnimalsMESH: MiceMESH : Mice Inbred BALB CMESH: Cholera Toxin030304 developmental biology030306 microbiologyRotavirus VaccinesRectumVirionMESH : Immunizationbiochemical phenomena metabolism and nutritionSecretoryVirologyImmunoglobulin AMESH: Immunoglobulin A SecretoryImmunizationInsect ScienceImmunologyImmunoglobulin A Secretorybiology.proteinMESH: OligodeoxyribonucleotidesbacteriaImmunizationMESH : AnimalsMESH: FemaleMESH: Antibodies Viral
researchProduct

A protective role for interleukin 18 in interferon γ-mediated innate immunity to Cryptosporidium parvum that is independent of natural killer cells.

2012

Innate immunity against some intracellular parasitic protozoa involves interleukin 18 (IL-18)-mediated interferon γ (IFN-γ) production by natural killer (NK) cells, but the role of IL-18 in innate resistance to Cryptosporidium infection is unknown. Adult Rag2(-/-)γc(-/-) mice that lack NK cells, T cells, and B cells demonstrated resistance to Cryptosporidium parvum infection that was IFN-γ dependent. Treatment with anti-IL-18-neutralizing antibodies resulted in loss of resistance correlating with reduced intestinal IFN-γ expression. Intestinal mature IL-18 expression increased in vivo during infection and also in the intestinal epithelial cell line CMT-93 following combined IFN-γ treatment/…

medicine.medical_treatmentMicrobiologyInterferon-gammaMiceInterferonmedicineImmunology and AllergyMacrophageAnimalsInterferon gammaRNA MessengerCells CulturedCryptosporidium parvumInnate immune systembiologyMacrophagesInterleukin-18Epithelial Cellsbiology.organism_classificationInterleukin-12Immunity InnateIntestinesKiller Cells NaturalMice Inbred C57BLInfectious DiseasesCryptosporidium parvumCytokineImmunologyInterleukin 12Interleukin 18Spleenmedicine.drugThe Journal of infectious diseases
researchProduct

Modulación de la inflamación por compuestos bioactivos de H. polyrhizus y metabolitos endógenos: relevancia en la enfermedad de Crohn

2018

La enfermedad inflamatoria intestinal es un desorden crónico del tracto gastrointestinal caracterizado por la disfuncionalidad de la barrera epitelial e inflamación de la mucosa. Su etiología es desconocida y se cree que se trata de una respuesta exacerbada del sistema inmune del huésped a agentes microbianos y ambientales en individuos genéticamente susceptibles. Las principales formas idiopáticas de EII son la colitis ulcerosa (CU) y enfermedad de Crohn (EC); ambas comparten algunas características clínico-patológicas y síntomas, pero difieren en otras. La CU es un trastorno crónico, que se caracteriza por inflamación abscesos y ulceraciones en las criptas principalmente del colon. Por ot…

metabolitosinflamacióncompuestos bioactivos:CIENCIAS MÉDICAS ::Farmacología [UNESCO]enfermedad de crohnenfermedad inflamatoria intestinalUNESCO::CIENCIAS MÉDICAS ::Farmacología
researchProduct

The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guideline…

2010

Biological therapies are an important step in the management of Inflammatory Bowel Diseases. In consideration of high cost and safety issues there is the need to have clear recommendations for their use. Despite the American Gastroenterological Association and the European Crohn's and Colitis Organisation have published exhaustive Inflammatory Bowel Disease guidelines, national guidelines may be necessary as cultural values, economical and legal issues may differ between countries. For these reasons the Italian Society of Gastroenterology and the Italian Group for the study of Inflammatory Bowel Disease have decided to elaborate the Italian guidelines on the use of biologics in Inflammatory…

methods Tumor Necrosis Factor-alphaAnti-Inflammatory AgentsUlcerativeDiseaseGUIDELINESHumanized Antibodieetiology Pregnancy Pregnancy ComplicationGastroenterologyInflammatory bowel diseaseetiology Opportunistic InfectionCrohn DiseasePregnancyNeoplasmsMonoclonaldrug therapy Remission Inductionantagonists /&/ inhibitorsSettore MED/12 - GastroenterologiaRemission InductionGastroenterologyAntibodies MonoclonalUlcerative colitisAnti-Inflammatory AgentItalyadverse effects/therapeutic use Intestinal FistulaTumor necrosis factor alphaFemaleImmunosuppressive Agentsmedicine.drugbiological drugsmedicine.medical_specialtyIBDOpportunistic InfectionsAntibodies Monoclonal HumanizedAutoimmune Diseasesadverse effects/therapeutic use Autoimmune DiseaseInternal medicinemedicineAdalimumabIntestinal FistulaHumansColitisdiagnosis/drug therapy/surgery Italy Neoplasmadverse effects/therapeutic use AntibodieHepatologydrug therapy Female Humans Immunosuppressive Agentbusiness.industryTumor Necrosis Factor-alphaAdalimumabCancermedicine.diseaseInfliximabInfliximabdigestive system diseasesdrug therapy Crohn Diseaseetiology ColitiPregnancy ComplicationsColitis Ulcerativebusiness
researchProduct

Zespół przerostu bakteryjnego jelita cienkiego

2021

Zespół przerostu bakteryjnego jelita cienkiego (SIBO) jest heterogennym zespołem charakteryzującym się wzrostem liczby i/lub obecnością nietypowych bakterii w jelicie cienkim. Na złożoną etiologię SIBO składają się zaburzenia ochronnych mechanizmów przeciwbakteryjnych jak zmniejszona kwaśność soku żołądkowego, zewnątrzwydzielnicza niewydolność trzustki, zespoły niedoboru odporności oraz nieprawidłowości anatomiczne jak niedrożność jelita cienkiego, uchyłki, przetoki, hirurgiczna ślepa pętla, wcześniejsze resekcje krętniczo-kątnicze oraz zaburzenia ruchliwości. Objawy kliniczne SIBO mogą być niespecyficzne. Najczęściej występuje niestrawność, biegunka, wzdęcia, dyskomfort w jamie brzusznej. …

mikrobiotaSIBOIBSmicrobiotazespół przerostu bakteryjnego jelita cienkiegohydrogen breath testssmall intestine bacterial overgrowthwodorowe testy oddechowePostępy Mikrobiologii
researchProduct